Head-to-head · WeighScore
Luma Meds vs Omada Health
The verdict
Luma Meds takes it — 57.8/100 to 55.6/100.
Luma Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Fully online compounded GLP-1 telehealth offering semaglutide and tirzepatide injections from FDA-regulated 503A and 503B compounding pharmacies.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Luma Meds | Omada Health |
|---|---|---|
| WeighScore | 57.8/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #391 | #435 |
| Semaglutide | $249/mo (compounded) | Not disclosed |
| Tirzepatide | $299/mo (compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #391 · C
Strengths
- LegitScript certified — a credibility mark fewer compounded GLP-1 providers carry
- Free discreet shipping and unlimited 24/7 support on every plan
- Compounded semaglutide and tirzepatide from FDA-regulated 503A/503B pharmacies
- '100,000+ members treated' claim with physician-supervised online care
- 3-month bundle pricing brings semaglutide as low as $140/mo
Where it loses points
- Compounding pharmacy partner not publicly named
- States available not published
- Monthly semaglutide ($249/mo) is above many lower-cost compounded competitors
- No oral formulation options listed
- Compounded medications are not FDA-approved
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.